drugset
drugset / Trial / NCT05822180

Evaluation of the Efficacy and Safety of Nano-S1

NCT05822180 ↗

Phase 3 Completed 116 enrolled General Administration of Military Health, Tunisia
RandomizedSingle-groupQuadruple-blindTreatment

Summary

This study aims to assess the efficacy of the efficacy and safety of investigational drug (NanoS) in patients with mild to moderate COVID-19 at high risk for progression to severe COVID-19, including death.

Timeline

Start
2021-01-01
Primary completion
2022-01-01
Completion
2022-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject NANOS1 Unknown 30 ml Oral

Indications

pneumonia